When a former “shady” hedge fund manager, who has now been called the most hated man in America, Martin Shkreli punched prices higher on a life-saving drug by over 5,000 percent, it caused an uproar in Washington D.C., drawing the ire of U.S. presidential candidate Hillary Clinton on Twitter. A prevailing thought was that the Democratic debate Tuesday night would be a forum for biotech vitriol. That didn’t happen, and biotechs are rallying on the no news is good news mantra.
I am pretty sure @MartinShkreli is pissed he didnt get a #DemocraticDebate shoutout
— Dan Rosenblum (@sharkbiotech) October 14, 2015
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
